Full-Time

Senior Director

Translational Research Scientist, MD/PhD

Intuitive Surgical

Intuitive Surgical

10,001+ employees

Manufactures robotic surgical systems and services

No salary listed

Sunnyvale, CA, USA

Hybrid

Remote/work-from-home with up to 20% travel; relocation not required; partial overlap with Pacific Time.

PhD, MD

Category
Biology & Biotech (1)
Required Skills
Pharmacology
Data Analysis
Google Cloud Platform

Get referred to Intuitive Surgical

See people who can refer or advise you

Requirements
  • Education: MD/PhD, or equivalent advanced degree in bioengineering, biomedical engineering, physiology, pharmacology, or related field.
  • 5+ years experience in translational research for medical devices, combination products, or biologics with direct responsibility for study design and execution.
  • Strong organizational skills, attention to detail, and ability to manage multiple projects and timelines.
  • Excellent written and verbal communication skills essential for successful long-term relationships with external collaborators.
  • Ability to analyze complex biological and engineering data, produce study reports, and present findings to technical and nontechnical stakeholders.
Responsibilities
  • Design and Execute Translational Study Plans
  • These may include in vitro, ex vivo, and/or in vivo studies to evaluate mechanism of action, performance, and safety of medical devices
  • Develop and validate experimental models, assays, and protocols that characterize clinical outcomes and support regulatory filings
  • Analyze and interpret study data then synthesize findings into study reports focusing on implications for medical device development and clinical study design.
  • Manage data integrity and study documentation per requirements including GLP (Good Laboratory Practice)/GCP (Good Clinical Practice) best practices for research.
  • Investigator & Site Engagement
  • Relationship Building: Identify subject matter expert collaborators. Build and sustain strongdeep, trusted relationships with collaborating investigators, labs and study sites.
  • Site Awareness: Maintain awareness of study progress with collaborating labs.
  • Communication: Establish and maintain open lines of communication with principal investigators and collaborating scientists.
  • Subject Matter Representation: Serve as a trusted collaborator to investigators and site teams, capable of discussing the underlying science and potential implications for medical device design as well as clinical implications..
  • Exploratory Research: Facilitate exploratory research by identifying opportunities for sub‑studies, brainstorming novel investigation areas, and assisting with publication efforts.
  • Clinical & Technical Expertise
  • Act as the internal expert on the clinical application, technical performance, and limitations of treatment platforms.
  • Translate clinical experience into insights related to safety, efficacy, usability, and procedural outcomes.
  • Identify and characterize patient subgroups most likely to benefit, including anatomical, physiological, and disease-specific factors.
  • Product & Engineering Learnings
  • Convert clinical findings into actionable inputs for product development and design evolution.
  • Influence product roadmap and development priorities based on real-world clinical use.
  • Support validation of safety and efficacy for products not yet on label across multiple trials.
  • Commercial Collaboration & Field Harmony
  • Serve as a key communication bridge with Commercial teams to ensure alignment across shared clinical and commercial pulmonary sites.
  • Provide regular, structured updates on site activity, investigator engagement, and trial progress.
  • Collaborate on which investigators and KOLs to prioritize, ensuring coordinated outreach and consistent communication.
  • Support harmony between clinical trial activity and existing commercial product presence while maintaining strict compliance boundaries for not-on-label products.
  • Strategic Alliances & Sponsored Studies
  • Partner Collaboration: Collaborate closely with strategic alliance partners conducting sponsored studies.
  • Study Guidance: Provide clinical and technical oversight to ensure sponsored studies align with overall product strategy, evidence-generation goals, and data quality expectations.
  • Outcomes Integration: Maintain visibility into progress, learnings, and outcomes from strategic alliance-led studies, i.
  • Integrating thesee insights from sponsored external studies into internal clinical, engineering, and product decision-making.
  • Cross-Functional Integration & Strategy
  • Strategic Connector: Serve as the primary liaison aligning Engineering, Clinical Affairs, Medical Affairs, Regulatory, and Data Analytics with data generated from translational projects.
  • Commercial Readiness: Ensure that learnings and data from studies are packaged to support regulatory submissions, device design, clinical study design, and marketing claims.
  • Team Leadership & Scaling
  • Function Building: Define the standard operating procedures for the translational research scientist feedback loop within the organization.
  • Mentorship & Growth: Recruit, train, and mentor a growing team of translational research scientists and specialists as the product pipeline matures.
  • Build and manage external collaborations with academic labs, contract research organizations (CROs), and clinical partners to expand capacity and access specialized expertise.
  • Scale translational capabilities: develop standardized models, assay platforms, and automation to increase throughput and reproducibility (ie biospecimen processing – staining and imaging, data storage, data sharing, data interpretation, others)
  • Cross-Functional Coordination & Team Growth
  • Coordinate across Clinical, Engineering, Medical, Regulatory, Data Analytics, Commercial, and Strategic Alliance teams.
  • Ensure clinical and technical insights are captured, analyzed, and disseminated in a timely and structured manner.
  • As clinical activity scales, help define team structure and lead the growth of a clinical engineering learnings function.
Desired Qualifications
  • Prior experience building or managing a research laboratory including lab technicians, PhD students/candidates, and/or postdoctoral researchers.
  • Understanding of regulatory pathways for medical devices (e.g., FDA and EU requirements) and experience designing studies to support submissions.
  • Experience with GLP-compliant study execution or working with CROs under GLP frameworks.
  • Experience establishing external academic or CRO partnerships and negotiating study agreements.

Intuitive Surgical designs, manufactures, and sells robotic surgical systems and provides related services and accessories for minimally invasive surgery. The core product helps surgeons perform operations with enhanced precision by guiding robotic arms controlled from a console, allowing procedures to be done through small incisions. Instruments and consumables are used with the systems and are supported by service contracts, creating a recurring revenue stream. Compared to competitors, Intuitive has a large installed base and focuses specifically on robotic-assisted surgery, combining devices, disposable instruments, and ongoing services to support hospitals and surgical centers. Its goal is to improve patient outcomes by enabling safer, less invasive procedures while expanding the use and capabilities of robotic surgery for more procedures and providers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

1995

Get referred to Intuitive Surgical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 19% to $2.89 billion, beating estimates on July 16.
  • Penang lease adds 316,000 square feet and 1,200 jobs, supporting Asia-Pacific growth.
  • Management kept 2026 da Vinci growth at 13.5%-15.5% and raised gross-margin guidance.

What critics are saying

  • FDA recall tracker listed multiple 2026 da Vinci Class II recalls, signaling quality-control strain.
  • Medtronic Hugo gained U.S. urology clearance in December 2025, tightening robotic-surgery competition.
  • 2027 extended instrument-use changes risk recurring revenue erosion if hospitals delay upgrades.

What makes Intuitive Surgical unique

  • Da Vinci installed base neared 13,000 systems worldwide, locking in switching costs.
  • Da Vinci 5 launched broadly in the U.S. in 2025, boosting utilization.
  • Ion procedures grew 36% in Q2 2026, extending Intuitive beyond soft-tissue robotics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 19th, 2026
Abbott beats Q2 estimates with 13% sales growth as diagnostics surge 42%, while Intuitive Surgical posts 19% revenue rise

Abbott Laboratories reported strong fiscal Q2 2026 results, with sales rising 13% on a reported basis and 4.8% on a comparable basis, beating estimates and prompting the company to raise its annual profit forecast. The diagnostics segment was particularly strong, growing 42% to $3.09 billion, driven by its cancer diagnostics business following the Exact Sciences acquisition. Intuitive Surgical also exceeded expectations in Q2 2026, with revenue growing 19% to $2.89 billion and adjusted EPS of $2.80, beating forecasts by $0.30. The company placed 468 da Vinci units during the quarter, an 18% year-over-year increase, whilst maintaining a non-GAAP gross margin of 70.0%. The companies present contrasting investment cases: Abbott offers diversified healthcare portfolio resilience, whilst Intuitive Surgical relies on its robotic surgery ecosystem with recurring revenue comprising approximately 85% of total sales.

PR Newswire
Aug 17th, 2026
Intuitive leases 316,000-sq-ft facility in Penang to manufacture surgical instruments, create 1,200 jobs by 2032

Intuitive, the global leader in minimally invasive care and pioneer of robotic-assisted surgery, has signed a lease agreement with Penang Development Corporation for a new manufacturing facility in Malaysia. The 316,000-square-foot site in Bandar Cassia Technology Park will produce surgical instruments and electromechanical devices for Intuitive's da Vinci surgical system. The facility is expected to begin operations in 2028 and create 1,200 highly skilled jobs by 2032. The investment reflects Intuitive's commitment to Asia Pacific, where its da Vinci systems have treated more than 2.5 million patients across 13 markets over two decades. The expansion aims to support growing demand for robotic-assisted surgery across the region and strengthen Penang's position as a MedTech manufacturing hub in Southeast Asia.

Yahoo Finance
Aug 16th, 2026
Oppenheimer upgrades Intuitive Surgical to 'Outperform' with $500 price target

Oppenheimer upgraded Intuitive Surgical from "Perform" to "Outperform" with a $500 price target, implying a 24.6% upside. The analysts expect the medtech company to maintain its leading position in robotic surgery despite increasing competition. Intuitive reported strong Q2 results, with revenue rising 18.5% year-over-year to $2.89 billion, surpassing analyst expectations. Non-GAAP earnings per share climbed 27.9% to $2.80, beating the $2.50 estimate. The company placed 468 da Vinci surgical systems and 55 Ion endoluminal systems during the quarter. Combined da Vinci and Ion procedures rose approximately 16% globally. Wall Street maintains a "Strong Buy" consensus rating on the stock, with 22 of 31 analysts recommending a strong buy. The consensus price target of $480.93 represents a 19.85% upside.

Yahoo Finance
Aug 12th, 2026
Intuitive Surgical's valuation barely budges despite two years of growth forecasts

Intuitive Surgical trades at $401.23, down 32% from its 52-week high and 15% over twelve months. The stock currently trades at 37.7 times trailing adjusted earnings. Analysts forecast earnings of $12.08 per share by 2027, bringing the multiple down to 33 times — only 13% lower despite two years of growth. Consensus projects 7% annual earnings growth and 9.7% revenue growth, suggesting margin compression ahead. Management raised its 2026 gross profit margin guidance to 68-69%. However, the company plans to extend instrument use limits starting in the first half of 2027 to lower procedure costs and boost adoption. Intuitive has not finalised pricing for this programme, creating uncertainty around 2027 estimates. The company will quantify the impact on its next earnings call.

Yahoo Finance
Aug 8th, 2026
Medtronic and Intuitive Surgical lag market amid sector weakness

Medtronic and Intuitive Surgical, two medical device leaders, have underperformed this year due to sector weakness and company-specific challenges. However, both show potential for recovery. Medtronic's fourth-quarter revenue rose 9.9% to $9.8 billion, though adjusted earnings per share fell 4.3% to $1.55 due to higher costs, including tariffs. The company posted its highest annual revenue growth in a decade, driven partly by its Pulse Field Ablation franchise. Medtronic recently received FDA clearance for its Hugo robotic-assisted surgery system for urologic procedures, positioning it to compete in the underpenetrated robotic surgery market. The company plans to spin off its lower-margin diabetes care division, which should improve margins. With a 3.4% forward dividend yield and 49 consecutive years of payout increases, Medtronic appeals to income-focused investors.